Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 14, 2013. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 619,000 Ordinary Shares of 25 pence each.
- Purchase Date: November 14, 2013.
- Price Range: Highest price paid was 1,620.50 pence per share; lowest price paid was 1,610.00 pence per share.
- Treasury Holdings (Settled): 508,442,412 shares (9.47% of total issued share capital).
- Treasury Holdings (Including Unsettled): 509,618,412 shares (10.48% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,862,666,685 shares.
Material Changes
The filing reports an incremental increase in treasury shares following the purchase of 619,000 shares. Consequently, the percentage of total voting rights held in treasury increased to 10.48% when including unsettled purchases. The filing does not provide comparative data for prior periods regarding share counts or treasury holdings.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (4,862,666,685) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in treasury (10.48% including unsettled shares).
- Review the price paid per share (1,610.00 to 1,620.50 pence) against market prices on November 14, 2013.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.